Nitroarginine

Nω-Nitro-l-arginine
Names
	IUPAC name (2S)-2-Amino-5-[[amino(nitramido)methylidene]amino]pentanoic acid
	Other names N5-(nitroamidino)-l-Ornithine; (+)-NG-Nitroarginine; NG-nitro-l-Arginine, l-NG-Nitroarginine; L-NNA; L-NOARG; NG-Nitro-l-arginine; NG-Nitroarginine; NOLA; NSC 53662; Nitro-l-arginine; Nω-Nitro-l-arginine; Nω-Nitro-l-arginine; ω-Nitro-l-arginine; ω-Nitroarginine
Identifiers
CAS Number	2149-70-4 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL227744 ;
ECHA InfoCard	100.016.745
PubChem CID	440005;
UNII	7O8V7H6P2J ;
CompTox Dashboard (EPA)	DTXSID2042696 ;
	SMILES OC([C@@H](N)CCCNC(N[N+]([O-])=O)=N)=O;
Properties
Chemical formula	C6H13N5O4
Molar mass	219.201 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Nitroarginine, or N^ω-nitro-l-arginine, is a nitro derivative of the amino acid arginine.[1] It is an inhibitor of nitric oxide synthase and hence a vasoconstrictor. As such, it finds widespread use as a biochemical tool in the study of nitric oxide and its biological effects.[2]

Nitroarginine has been used in research studying coronary constriction, and it was found that, in the presence of midazolam vasodilatation was unaffected by nitroarginine.[3] Due to the presence of all three isoforms of nitric oxide synthase in striatal tissue in the forebrain, research has also been conducted on how its inhibition might affect monoamine transport and dopamine half-life in the striatal extracelullar space.[4]

References

Moore, P. K.; Al‐Swayeh, O. A.; Chong, N. W. S.; Evans, R. A.; Gibson, A. (1990). "l-NG-nitro arginine (l-NOARG), a novel, l-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro". British Journal of Pharmacology. 99 (2): 408–412. doi:10.1111/j.1476-5381.1990.tb14717.x. ISSN 1476-5381. PMC 1917379. PMID 2328404.
Bansinath M, Arbabha B, Turndorf H, Garg UC (1993). "Chronic administration of a nitric oxide synthase inhibitor, N^ω-nitro-L-arginine, and drug-induced increase in cerebellar cyclic GMP in vivo". Neurochemical Research. 18 (10): 1063–6. doi:10.1007/BF00966685. PMID 7504789.
O.L. Woodman; G.J. Dusting (1991). "N-nitro L-arginine causes coronary vasoconstriction and inhibits endothelium-dependent vasodilatation in anaesthetized greyhounds". Br. J. Pharmacol. 103 (2): 1407–1410. doi:10.1111/j.1476-5381.1991.tb09802.x. PMC 1908370. PMID 1909199.
Prieto, Sonia Guerrero; Silva, João Carlos dos Santos; de Lima, Mairon Oliveira; Almeida, Maria Camila; Echeverry, Marcela Bermúdez (February 2019). "Cross-tolerance between nitric oxide synthase inhibition and atypical antipsychotics modify nicotinamide-adenine-dinucleotide phosphate-diaphorase activity in mouse lateral striatum:". Behavioural Pharmacology. 30 (1): 67–78. doi:10.1097/FBP.0000000000000406. ISSN 0955-8810. PMID 29664745 – via Ovid.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Moore, P. K.; Al‐Swayeh, O. A.; Chong, N. W. S.; Evans, R. A.; Gibson, A. (1990). "l-NG-nitro arginine (l-NOARG), a novel, l-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro". British Journal of Pharmacology. 99 (2): 408–412. doi:10.1111/j.1476-5381.1990.tb14717.x. ISSN 1476-5381. PMC 1917379. PMID 2328404.

[2] Bansinath M, Arbabha B, Turndorf H, Garg UC (1993). "Chronic administration of a nitric oxide synthase inhibitor, N^ω-nitro-L-arginine, and drug-induced increase in cerebellar cyclic GMP in vivo". Neurochemical Research. 18 (10): 1063–6. doi:10.1007/BF00966685. PMID 7504789.

[3] O.L. Woodman; G.J. Dusting (1991). "N-nitro L-arginine causes coronary vasoconstriction and inhibits endothelium-dependent vasodilatation in anaesthetized greyhounds". Br. J. Pharmacol. 103 (2): 1407–1410. doi:10.1111/j.1476-5381.1991.tb09802.x. PMC 1908370. PMID 1909199.

[4] Prieto, Sonia Guerrero; Silva, João Carlos dos Santos; de Lima, Mairon Oliveira; Almeida, Maria Camila; Echeverry, Marcela Bermúdez (February 2019). "Cross-tolerance between nitric oxide synthase inhibition and atypical antipsychotics modify nicotinamide-adenine-dinucleotide phosphate-diaphorase activity in mouse lateral striatum:". Behavioural Pharmacology. 30 (1): 67–78. doi:10.1097/FBP.0000000000000406. ISSN 0955-8810. PMID 29664745 – via Ovid.